How Much Should We Exercises to Reduce Mortality?

Physical activity has been shown to reduce mortality in a dose/response manner, just like any drug. But many still wonder: are there any minimal requirements in terms of amount or intensity? Is there such a thing as “toxic exercise”? And finally, is exercising equally beneficial to all?

Programas de ejercicios en la enfermedad vascular periférica

This study, conducted by Dr Sang-Woo Jeong from the Cardiovascular Department of Seoul National University, published in the European Heart Journal, answers all these concerns. 

The current guidelines recommend between 500 and 1000 metabolic units (METs) minutes per week of regular physical activity. This is the same as telling our patients they can drink 20 gr of absolute alcohol per day. Patients stare back at us clueless, wondering the same we do. They want to know how many pints of beer, glasses of wine or whiskeys they can drink safely. It happens the same with exercise.


Read also: Supervised Exercise and Revascularization for Intermittent Claudication.


Light physical activity (such as leisurely walking or strolling) equals 2.9 METS; moderate physical activity (brisk walking, cycling or playing tennis doubles) equals 4 METS; and intense physical activity (running, cycling faster than 15 km/h, walking uphill fast or doing aerobics) equals 7 METS. 

Once identified, MET values should be multiplied by minutes per day and number of days a week the patient exercises (e.g. brisk walking for 40 minutes 4 days a week equals 640 MET minutes per week). A complete sedentary lifestyle equals 0 MET minutes/week.

This study included 131,558 individuals with cardiovascular disease and 310,240 individuals with no known cardiovascular disease followed for mean 5.9 years with all cause death as end point.


Read also: Exercise Programs in Peripheral Artery Disease.


There was an inverse correlation between physical activity and mortality in both populations. However, those with a history of cardiovascular disease (CVD) saw greater benefits from the same level of exercise than the ones with no history of CVD. For every 500 MET minutes per week of physical activity, there was a 14% reduction in mortality in patients with a history of CVD vs. 7% in patients with no history of CVD (p<0.001). In other words, the benefit of exercising is twice as high in the context of secondary prevention vs primary prevention. 

For patients with no history of CVD, one “dose” of exercise between 1 and 500 MET minutes per week seems enough, but individuals with CVD continue to benefit from 500 METS, even 1000 or more MET minutes per week. 

Adjusted mortality for CVD patients doing intense physical activity (>1000 MET minutes/week) is comparable and even lower than the group with no known CVD. This study tells us that CVD patient prognosis can be neutralized with regular exercise. Seeing as the cost/benefit ratio of exercising is still underestimated, it is without question essential to our consultation. 

2020-01-23-ehz564-abierto

Original Title: Mortality reduction with physical activity in patients with and without cardiovascular disease.

Reference: Sang-Woo Jeong et al. European Heart Journal (2019) 40, 3547–3555.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...